Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Post Marketing Surveillance Study on Emselex After Launch in Germany

This study has been completed.
Information provided by:
Bayer Identifier:
First received: November 5, 2008
Last updated: April 29, 2010
Last verified: April 2010

- Data are obtained of Emselex in routine treatment of Overactive Bladder. The general objectives are to evaluate the product safety, compatibility, efficacy and patient acceptance.

Condition Intervention Phase
Overactive Bladder
Drug: Darifenacin, Emselex (BAY79-4998)
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Post-Marketing Surveillance Study Emselex

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Adverse events, Adverse drug reactions, physician's global assessment of tolerability [ Time Frame: After 2-3 months of treatment (long-term 6 months) ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Incontinence [ Time Frame: At end of study ] [ Designated as safety issue: No ]
  • Urgency episodes [ Time Frame: At end of study ] [ Designated as safety issue: No ]
  • Micturitions / nycturitions [ Time Frame: At end of study ] [ Designated as safety issue: No ]
  • Physician's assessment of improvement/efficacy [ Time Frame: At end of study ] [ Designated as safety issue: No ]
  • Physician's assessment of patient's satisfaction with therapeutic effect [ Time Frame: At end of study ] [ Designated as safety issue: No ]
  • Physician's assessment of patient's ability to hold urine [ Time Frame: At end of study ] [ Designated as safety issue: No ]
  • Dose and treatment duration of Emselex [ Time Frame: At end of study ] [ Designated as safety issue: No ]

Enrollment: 5821
Study Start Date: January 2005
Study Completion Date: February 2006
Primary Completion Date: February 2006 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 Drug: Darifenacin, Emselex (BAY79-4998)
Patients from routine practice


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients from routine practice


Inclusion Criteria:

  • Patients who are treated with Emselex for Overactive Bladder

Exclusion Criteria:

  • Exclusion criteria are the contraindications as specified in the German product information
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00786448

Many Locations, Germany
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
No publications provided

Responsible Party: Medical Director, Bayer Schering Pharma AG Identifier: NCT00786448     History of Changes
Other Study ID Numbers: 12245, EX0501DE
Study First Received: November 5, 2008
Last Updated: April 29, 2010
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Bayer:
Overactive Bladder

Additional relevant MeSH terms:
Urinary Bladder, Overactive
Lower Urinary Tract Symptoms
Signs and Symptoms
Urinary Bladder Diseases
Urologic Diseases
Urological Manifestations
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Urological Agents processed this record on November 27, 2014